Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Remission of myasthenia gravis following infection with SARS-CoV-2: A case report.

Created on 16 Oct 2026

Authors

Che-Yu Lin, Shannon Su, Ann Yi-Chiun Chuang

Published in

Taiwan journal of ophthalmology. Volume 16. Issue 3. Pages 499-503. Epub Feb 05, 2025.

Abstract

This case report describes an unprecedented remission of ocular Myasthenia Gravis (MG) in a 3-year-old girl following a SARS-CoV-2 infection. Both MG and SARS-CoV-2 influence the cholinergic system, and this case underscores the importance of considering multiple factors in autoimmune disorders and the potential impact of viral infections on their course. The patient initially presented with ptosis and limited eye movement. Her diagnosis of seronegative MG was confirmed with abnormal visual evoked potentials and positive response to pyridostigmine. Her ptosis and limited extraocular muscle movement were intermittent until 2 years later when she tested positive for SARS-CoV-2 for which no antiviral medication was taken. Unexpectedly, her MG symptoms rapidly improved postinfection, leading to the cessation of pyridostigmine. This case highlights the complex interplay between MG, viral infections, and the influence of anti-acetylcholine receptor antibodies, second-hand smoke, and natural nicotinic agonists from the use of pyridostigmine on the cholinergic system.

PMID:
42877925
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement